Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Valuation
Historical valuation analysis based on 500 data points (2024-09-26 to 2026-09-24)
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high u...
Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) currently trades at a P/S ratio of 20.39 (range: 14.40–54.85, 38th percentile — below its historical average).
Madrigal Pharmaceuticals, Inc. Common Stock trades below its historical valuation range, with most metrics below their median levels.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/S Ratio | 20.39 | 14.40 | 23.40 | 54.85 | 38th | below its historical average |
Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Valuation & P/E History
Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry currently trading at $513.21 with a market capitalization of $11.9 billion. This page provides historical valuation analysis for MDGL based on 500 data points covering 2024-09-26 to 2026-09-24.. The P/S ratio of 20.39 compares to a median of 23.40.
MDGL Valuation Metrics & Historical Range
The valuation table above shows Madrigal Pharmaceuticals, Inc. Common Stock's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether MDGL is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests MDGL is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Madrigal Pharmaceuticals, Inc. Common Stock.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is MDGL Overvalued or Undervalued?
Madrigal Pharmaceuticals, Inc. Common Stock trades below its historical valuation range, with most metrics below their median levels. The overall valuation percentile of 38 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive MDGL is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full MDGL analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.MDGL trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.